6
Aug
2026
Takeda Wins First-in-Class Orexin OK, Lilly’s Obesity Money Gusher, & Three New IPOs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Aug
2026
LifeMine, In Verdine’s Big Year, Raises $263M For Safer Drug for Organ Transplants
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.